Skip to main content

Advertisement

SpringerLink
Log in

70 Gy or more: which dose for which prostate cancer?

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction: Radical prostatectomy and radiotherapy are currently accepted treatment modalities for localized prostate cancer. Regarding radiotherapy, current evidence suggests that favorable treatment outcome critically depends on adequate radiation doses. However, the exact role of dose in relation to the individual risk profile is complex. In order to evaluate available data on radiation dose response relationships, in prostate cancer, a thorough and critical literature analysis was performed. Material and methods: Studies on dose response relationships from randomized trials, dose escalation trials, retrospective subgroup analyses and pooled data were identified by Pubmed and ISI web of sciences searches and were critically reviewed. Results and conclusion: All available data suggest a clear dose response relationship for radiotherapy for localized prostate cancer. In low risk cases, most studies suggest that doses of 70–72 Gy are adequate. Dose escalations up to 78–80 Gy seem to be beneficial for intermediate risk patients. Due to confounding variables, the dose response curves for high-risk patients are less steep. The integration of dose escalation into a more comprehensive treatment protocol is difficult, since trials on the relative impact of either hormonal ablation or inclusion of adjuvant nodal regions on dose escalation are missing

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, Luporsi E, Pommier P, Cowen D, Gonzague-Casabianca L, Simonian-Sauve M, Maingon P, Naudy S, Lagrange J, Marcie S (2000) Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int J Radiat Oncol Biol Phys 48:513–517

    Article  CAS  PubMed  Google Scholar 

  • Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300

    Article  CAS  PubMed  Google Scholar 

  • Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  CAS  PubMed  Google Scholar 

  • Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH, Hogan C, Hayman JA (2002) Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 20:2869–2875

    Article  PubMed  Google Scholar 

  • Chuba PJ, Moughan J, Forman JD, Owen J, Hanks G (2001) The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys 50:325–334

    Article  CAS  PubMed  Google Scholar 

  • Coen JJ, Zietman AL, Thakral H, Shipley WU (2002) Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20:3199–3205

    Article  PubMed  Google Scholar 

  • Crook JM, Perry GA, Robertson S, Esche BA (1995) Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45:624–31; discussion 631–632

    Article  CAS  PubMed  Google Scholar 

  • Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353:267–272

    Article  CAS  PubMed  Google Scholar 

  • Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM (2000) 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 47:335–342

    Article  CAS  PubMed  Google Scholar 

  • Fossa SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003) Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 57:33–41

    Article  PubMed  Google Scholar 

  • Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF (1991) The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 21:537–547

    CAS  PubMed  Google Scholar 

  • Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90

    Article  PubMed  Google Scholar 

  • Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P (2002) Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167:123–126

    Article  CAS  PubMed  Google Scholar 

  • Hanks GE, Leibel SA, Krall JM, Kramer S (1985) Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 11:153–157

    CAS  PubMed  Google Scholar 

  • Hanks GE, Martz KL, Diamond JJ (1988) The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299–1305

    CAS  PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510

    Article  CAS  PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE (1999) Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5:152–158

    CAS  PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823–832

    Article  CAS  PubMed  Google Scholar 

  • Hanks GE, Hanlon AL, Epstein B, Horwitz EM (2002) Dose response in prostate cancer with 8–12 years’ follow-up. Int J Radiat Oncol Biol Phys 54:427–435

    Article  PubMed  Google Scholar 

  • Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 21:3972–3978

    Article  CAS  PubMed  Google Scholar 

  • Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M (2001) Subset analysis of RTOG 85–31 and 86–10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49:947–956

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D’Amico AV (2002) Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys 53:1106–1110

    Article  PubMed  Google Scholar 

  • Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA (2000) Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352–3359

    CAS  PubMed  Google Scholar 

  • Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A (2002) Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54:686–697

    Article  PubMed  Google Scholar 

  • Kuban DA, el-Mahdi AM, Schellhammer PF (1987) Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 30:420–426

    Article  CAS  PubMed  Google Scholar 

  • Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL (2003) Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915–928

    Article  PubMed  Google Scholar 

  • Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA (2001a) Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason < or =6, and pretreatment prostate-specific antigen < or =10). Int J Radiat Oncol Biol Phys 50:621–625

    Article  CAS  PubMed  Google Scholar 

  • Kupelian PA, Reddy CA, Klein EA, Willoughby TR (2001b) Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51:988–993

    Article  CAS  PubMed  Google Scholar 

  • Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20:3376–3385

    Article  PubMed  Google Scholar 

  • Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33

    Article  PubMed  Google Scholar 

  • Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946

    Article  CAS  PubMed  Google Scholar 

  • Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC (2000) Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models. Int J Radiat Oncol Biol Phys 47:1245–1260

    Article  CAS  PubMed  Google Scholar 

  • Levegrun S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, Fuks Z, Leibel SA, Ling CC (2002) Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63:11–26

    Article  PubMed  Google Scholar 

  • Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH (2001) Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19:1619–1628

    CAS  PubMed  Google Scholar 

  • Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A (2003) Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 57:377–383

    Article  PubMed  Google Scholar 

  • Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M (1999) Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 44:921–929

    Article  CAS  PubMed  Google Scholar 

  • Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252

    Article  CAS  PubMed  Google Scholar 

  • Pinover WH, Hanlon AL, Horwitz EM, Hanks GE (2000) Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/ml prostate cancer. Int J Radiat Oncol Biol Phys 47:649–654

    Article  CAS  PubMed  Google Scholar 

  • Pollack A, Smith LG, von Eschenbach AC (2000a) External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48:507–512

    Article  CAS  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000b) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904–3911

    CAS  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  • Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC (2000) Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 92:1582–1592

    Article  CAS  PubMed  Google Scholar 

  • Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC (1997) Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 37:31–39

    Article  CAS  PubMed  Google Scholar 

  • Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Mohuidden M (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609–615

    Article  CAS  PubMed  Google Scholar 

  • Roach M III, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911

    Article  PubMed  Google Scholar 

  • Ross PL, Scardino PT, Kattan MW (2001) A catalog of prostate cancer nomograms. J Urol 165:1562–1568

    Article  CAS  PubMed  Google Scholar 

  • Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD (2002) Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54:1036–1046

    Article  PubMed  Google Scholar 

  • Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ et al (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3–12

    Article  CAS  PubMed  Google Scholar 

  • Singh A, Zelefsky MJ, Raben A, Lombardi D, Leibel SA (2000) Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer 90:275–280

    Article  CAS  PubMed  Google Scholar 

  • Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM (2003) Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57:384–390

    Article  PubMed  Google Scholar 

  • Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A (2003) Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929–943

    Article  CAS  PubMed  Google Scholar 

  • Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D (2000) Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18:2740–2746

    CAS  PubMed  Google Scholar 

  • Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20:557–566

    PubMed  Google Scholar 

  • Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE, Sherman NE (1991) The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 68:2370–2377

    CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491–500

    Article  CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA (1999) Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17:517–522

    CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876–881

    Article  CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Tübingen, Hoppe Seyler Str. 3, 72076, Tübingen, Germany

    U. Ganswindt, F. Paulsen, M. Bamberg & C. Belka

  2. Department of Urology, University of Tübingen, Hoppe Seyler Str. 3, 72076, Tübingen, Germany

    A. G. Anastasiadis & A. Stenzl

Authors
  1. U. Ganswindt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Paulsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. G. Anastasiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Bamberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Belka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Belka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganswindt, U., Paulsen, F., Anastasiadis, A.G. et al. 70 Gy or more: which dose for which prostate cancer?. J Cancer Res Clin Oncol 131, 407–419 (2005). https://doi.org/10.1007/s00432-005-0681-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-005-0681-0

Keywords

Search

Navigation